Marvel Biosciences Corp. (MRVL) has provided a corporate update on its operations and strategies for redeveloping existing drugs against new diseases.
The safety profile of drug candidates is considered predictable. As a new novel drug, it would be fully protected by patents.
After showing promising results in pre-clinical studies, Marvel’s lead candidate, MB-204, is about to enter clinical trials.
The trials will determine early indications of efficacy in treating depression and anxiety through effects on attention and motivation.
Last year Marvel’s pre-clinical data suggested that MB-204 could be dosed as a once-a-day oral agent.
MB-204 has also shown indications of being able to treat non-alcoholic steatohepatitis (NASH).
MB-204 showed a reduction in NAS scores in multiple model NASH, and a 47 per cent reduction in liver fibrosis.
It has outperformed the leading phase III anti-fibrotic drug, Cenicriviroc, in a head-to-head study.
Over the course of 2022, there are several key milestones that Marvel expects to deliver.
The first being a maximum tolerated dose study to establish the dose that produces an acceptable level of toxicity or not.
Marvel will also execute toxicology studies to understand the onset, degree of severity, and time length to which a particular dose of a MB-204 demonstrates any toxic effects.
If proven successful in these studies, MB-204 will enter human clinical studies.
Marvel Biosciences Corp. (MRVL) is unchanged trading at $0.20 per share as of 9:48 a.m. EST.